TSXV - Delayed Quote CAD

Hemostemix Inc. (HEM.V)

0.2400

+0.0400

+(20.00%)

At close: January 10 at 3:58:55 PM EST

Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up

Calgary, Alberta--(Newsfile Corp. - January 9, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) is pleased to announce amendments to its Manufacturing Services Agreement with CytoImmune Therapeutics ("CytoImmune"). These amendments add Regulatory Consulting and Engineering Services and align payments made by Hemostemix PR Inc. with the policies of both the TSX Venture Exchange and Puerto Rico's ACT 60 Program.Driving Regulatory and Engineering InnovationCytoImmune's regulatory expert

Newsfile yesterday

HMTXF
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash

Calgary, Alberta--(Newsfile Corp. - January 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has incorporated Hemostemix PR Inc., in Puerto Rico, as a wholly owned subsidiary and a domestic for profit corporation.Under Puerto Rico's ACT 60 program, Hemostemix PR Inc. is eligible to file applications for cash reimbursement of up to 50% of its research and development expenses, including clinical trials, ...

Newsfile 4 days ago

HMTXF
Hemostemix is Up-Listing in the USA to Generate Liquidity

Calgary, Alberta--(Newsfile Corp. - January 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has applied to up-list its shares on the OTCQB Venture Market. Currently listed on the TSXV Exchange, Frankfurt, and the OTC, Hemostemix aims to increase its liquidity by broadening its reach to all investors who trade in the capital markets of the USA, Europe, and Canada.The Company's social ...

Newsfile 8 days ago

HMTXF
Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction

Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating individuals about treatments and advancements.Calgary, Alberta--(Newsfile Corp. - December 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X is gaining traction. This campaign aims to share patient su

Newsfile 10 days ago

HMTXF
Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments

Hemostemix is revolutionizing how individuals think about their own regenerative medicine treatments. With social media, the company is educating about its treatments and advancements. Calgary, Alberta--(Newsfile Corp. - December 17, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the launch of its social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X. This campaign aims to share patient success stories, con

Newsfile 24 days ago

HMTXF
Hemostemix Announces $2,725,982 Update to Second Closing

Calgary, Alberta--(Newsfile Corp. - December 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is amending its closing documents to include an additional subscription of $50,000. The combined Offerings resulted in gross proceeds of $2,725,981.77 upon the issuance of 54,519,635 Units. The Offering is subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued in connection

Newsfile last month

HMTXF
Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258

Calgary, Alberta--(Newsfile Corp. - November 28, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its second and final tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $833,258 (the "Offering"). The Offering consisted of the issuance of an aggregate of 16,665,160 Units at a price of $0.05 per Unit. Each Unit consists of ...

Newsfile last month

HMTXF
Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway

Calgary, Alberta--(Newsfile Corp. - November 25, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, focusing on revenue, it has retained social media experts to educate and sell caregivers and individuals suffering from Chronic Limb Threatening Ischemia ("CLTI"), Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy, and Congestive Heart Failure, an ACP-01 treatment, available under special access programs.ACP-01 is a

Newsfile last month

HMTXF
Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement

Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of $1,842,723 (the "Offering"). The Offering consisted of the issuance of an aggregate of 36,854,475 Units at a price of $0.05 per Unit. Each Unit consists of one ...

Newsfile 2 months ago

HMTXF
Hemostemix's Private Placement

Calgary, Alberta--(Newsfile Corp. - October 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $4,000,000 of financing in tranches from the sale of Common Shares and Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one common share purchase warrant ("Warrant"), with each Warrant entitling the ...

Newsfile 2 months ago

HMTXF
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01

Calgary, Alberta--(Newsfile Corp. - August 1, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it and CytoImmune Therapuetics ("CytoImmune") today signed a binding and funded definitive Manufacturing Services Agreement that re-establishes production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility in Toa Baja, Puerto Rico. CytoImmune Therapeutics, Toa Baja, Puerto RicoTo view an enhanced version of this graphic, pleas

Newsfile 5 months ago

HMTXF
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment

Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it was notified by the World Intellectual Property Organization that it was granted the trademark Your Fountain of Youth by the Swiss Trademark Office. "In four heart and three chronic limb threatening ischemia (CLTI) trials, including one retrospective study of 54 patients, ACP-01 is demonstrated to be safe and statistically efficacious ...

Newsfile 6 months ago

HMTXF
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments

Calgary, Alberta--(Newsfile Corp. - June 3, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) is pleased to announce it has signed a Letter of Intent ("LOI") with CytoImmune Therapuetics ("CytoImmune") to re-establish production of ACP-01 ("ACP") in CytoImmune's state-of-the-art clinical cell manufacturing facility. The Company is also pleased to announce that it has received commitments for $1,800,000 of Units in a non-brokered private placement as more fully described below.Cyt

Newsfile 7 months ago

HMTXF
Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Calgary, Alberta--(Newsfile Corp. - March 7, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the non-exclusive engagement of Oak Hill Asset Management Inc. ("OHAM"), an Exempt Market Dealer to provide capital markets advice related to the Company's capital markets strategy. Services include advice on the structure of equity or debt capital financing and the identification of potential future investors. The Company intends to .

Newsfile 9 months ago

HMTXF
Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Calgary, Alberta--(Newsfile Corp. - February 6, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Journal of Biomedical Research and Environmental Sciences published the Company's Phase II randomized clinical trial results today.The publication highlights the results of no option critical limb ischemia patients who started the clinical trial with an ulcer, comparing wound healing, amputation, and mortality between the patien

Newsfile 10 months ago

HMTXF

Performance Overview

Return	HEM.V	S&P/TSX Composite index
YTD	+242.86%	+0.60%
1-Year	+220.00%	+18.10%
3-Year	+50.00%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hemostemix Inc. (HEM.V)

Hemostemix and CytoImmune Amend Manufacturing Agreement to Accelerate Global Scale-Up

Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% Reimbursement of R&D Expenses in Cash

Hemostemix is Up-Listing in the USA to Generate Liquidity

Hemostemix's Social Media Awareness of "Your Fountain of Youth"(TM) Regenerative Medicine Treatments Is Gaining Traction

Hemostemix Drives Social Media Awareness of Its Regenerative Medicine Treatments

Hemostemix Announces $2,725,982 Update to Second Closing

Hemostemix Announces $2,675,981 Private Placement Including Second Tranche of $833,258

Hemostemix Announces ACP-01 Treatment-Purchase Available with Social Media Campaign Underway

Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement

Hemostemix's Private Placement

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01

Hemostemix Announces Trademark Granted by Switzerland and Interest Payment

Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences

Performance Overview